Clinical Trial

Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy

Study acronym: MSC-ICAHT
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-30.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT07212335
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Immune Effector Cell Associated Hematotoxicity
Enrollment 15 participants
Start Date 2025-10-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-11